Researchers at the University of California, San Diego School of Medicine, the National Institutes of Health (NIH) and the Mayo Clinic have published promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy. Their study will be published in the April 21 issue of the Journal of the American Society of Nephrology (JASN)…. Read the full story from the UCSD Newsroom
Kumar Sharma, MD, FAHA, is Professor of Medicine in the Division of Nephrology-Hypertension and Director of the UCSD Center for Renal Translational Medicine. He is lead investigator of the study, which was published in the April 21 issue of Journal of the American Society of Nephrology (JASN). Read the abstract of the published report.